Tandem Diabetes Care (TNDM) Shares Outstanding (Weighted Average) (2013 - 2026)

Tandem Diabetes Care has reported Shares Outstanding (Weighted Average) for 14 years, with the latest figure at $68.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.0% year-over-year to $68.4 million; the trailing twelve-month figure through Mar 2026 stood at $68.4 million (up 3.0% YoY), and the FY2024 full-year result was $65.9 million, up 1.49% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $68.4 million, up from $193788.0 in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $68.4 million in Q1 2026, with the low at $193788.0 in Q3 2023.
• Historically, Shares Outstanding (Weighted Average) has averaged $57.2 million across 5 years, with a median of $64.9 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) surged 33719.43% — and 2025, when it sank 99.7%.
• Tandem Diabetes Care's Shares Outstanding (Weighted Average) stood at $64.1 million in 2022, then climbed by 1.28% to $65.0 million in 2023, then rose by 1.49% to $65.9 million in 2024, then sank by 99.71% to $193788.0 in 2025, then jumped by 35194.76% to $68.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $68.4 million (Q1 2026), $193788.0 (Q3 2025), and $67.0 million (Q2 2025), per Business Quant data.